SCHEMBL20875256

SCHEMBL20875256

CC(O)c1n[nH]c2ccc(Br)cc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 3/20 0.54
JAK2 O60674 3/20 0.54
DYRK1A Q13627 4/20 0.49
FLT3 P36888 3/20 0.49
CLK4 Q9HAZ1 3/20 0.49
PRKD3 O94806 2/20 0.49
MAP4K4 O95819 2/20 0.49
CSF1R P07333 2/20 0.49
CLK2 P49760 2/20 0.49
CSNK2A1 P68400 2/20 0.49
MAP4K2 Q12851 2/20 0.49
NTRK3 Q16288 2/20 0.49
AURKB Q96GD4 2/20 0.49
DCLK1 O15075 1/20 0.49
CHEK2 O96017 1/20 0.49
FER P16591 1/20 0.49
CDK2 P24941 1/20 0.49
MARK3 P27448 1/20 0.49
FLT4 P35916 1/20 0.49
MAPK9 P45984 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL877445 0.86 PDPK1 (0.58) PDPK1JAK2DYRK1AFLT3CLK4
SCHEMBL23068049 0.80 PDPK1 (0.47) PDPK1JAK2DYRK1AFLT3CLK4
SCHEMBL27771849 0.80 MEN1 (0.44) DYRK1AHTR2AHTR2CFADS1GSK3B
SCHEMBL27750998 0.80 FADS1 (0.43) JAK2DYRK1AHTR2AFADS1GSK3B
SCHEMBL31482872 0.79 PDPK1 (0.58) PDPK1JAK2DYRK1AFLT3CLK4
SCHEMBL23067968 0.77 PDPK1 (0.47) PDPK1JAK2DYRK1AFLT3CLK4
SCHEMBL905992 0.76 PDPK1 (0.54) PDPK1JAK2DYRK1AFLT3CLK4
SCHEMBL27771845 0.75 KDM4E (0.48) PDPK1FLT3CDK2FGFR1FLT1
SCHEMBL27771844 0.74 MAPT (0.55) CSNK2A1CDK2NOS1LMNAHPGD
SCHEMBL29790490 0.73 GSK3B (0.48) PDPK1JAK2DYRK1AFLT3CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10556908-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors INCYTE CORPORATION (US) 2020-02-11 US disclosed
US-20190106426-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS INCYTE CORPORATION 2019-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556908-B2 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors KDM1A, KDM1B, KDM2A PDPK1 1819/4885JAK2 451/4885DYRK1A 2744/4885
US-20190106426-A1 IMIDAZOPYRAZINES AS LSD1 INHIBITORS KDM1B, KDM2A, KDM1A PDPK1 1263/4885JAK2 1212/4885DYRK1A 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.